collection
MENU ▼
Read by QxMD icon Read
search

HIV

shared collection
194 papers 100 to 500 followers
https://www.readbyqxmd.com/read/28327461/muscle-strength-is-impaired-in-men-but-not-in-women-living-with-hiv-taking-antiretroviral-therapy
#1
Vitor Hf Oliveira, Susana L Wiechmann, Argéria Ms Narciso, Allison R Webel, Rafael Deminice
BACKGROUND: There is evidence that HIV Antiretroviral Therapy adverse effects may be sex-dependent, but data examing these sex differences in muscle strength is scarce. Our aim was to compare dynamic and isokinetic parameters of muscle strength between HIV-infected men and women to HIV-uninfected subjects. METHODS: In this cross-sectional study, muscle strength was evaluated in 44 HIV-infected (20 men, 24 women) and 25 age-, race- and body mass index-matched HIV-uninfected subjects (11 men, 14 women)...
March 22, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28315199/hiv-infection-and-risk-of-cardiovascular-diseases-beyond-coronary-artery-disease
#2
REVIEW
Revery P Barnes, John Charles A Lacson, Hossein Bahrami
PURPOSE OF REVIEW: Cardiovascular disease (CVD) increasingly afflicts people living with HIV (PLWH) in the contemporary era of antiretroviral therapy (ART). Coronary artery disease (CAD) is the most widely studied cardiovascular problem in PLWH; however, less is known about other clinically relevant subtypes of CVD such as heart failure (HF), cerebrovascular disease, sudden cardiac death, pericardial diseases, and pulmonary hypertension. This paper reviews evidence of other subtypes of CVD as emerging issues in the post-ART era...
May 2017: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/28264054/delineating-cd4-dependency-of-hiv-1-adaptation-to-infect-low-level-cd4-expressing-target-cells-widens-cellular-tropism-but-severely-impacts-on-envelope-functionality
#3
David Beauparlant, Peter Rusert, Carsten Magnus, Claus Kadelka, Jacqueline Weber, Therese Uhr, Osvaldo Zagordi, Corinna Oberle, Maria J Duenas-Decamp, Paul R Clapham, Karin J Metzner, Huldrych F Günthard, Alexandra Trkola
A hallmark of HIV-1 infection is the continuously declining number of the virus' predominant target cells, activated CD4+ T cells. With diminishing CD4+ T cell levels, the capacity to utilize alternate cell types and receptors, including cells that express low CD4 receptor levels such as macrophages, thus becomes crucial. To explore evolutionary paths that allow HIV-1 to acquire a wider host cell range by infecting cells with lower CD4 levels, we dissected the evolution of the envelope-CD4 interaction under in vitro culture conditions that mimicked the decline of CD4high target cells, using a prototypic subtype B, R5-tropic strain...
March 2017: PLoS Pathogens
https://www.readbyqxmd.com/read/27902590/genotypic-distribution-of-hhv-8-in-aids-individuals-without-and-with-kaposi-sarcoma-is-genotype-b-associated-with-better-prognosis-of-aids-ks
#4
Tania Regina Tozetto-Mendoza, Karim Yaqub Ibrahim, Adriana Fumie Tateno, Cristiane Mendes de Oliveira, Laura Massami Sumita, Maria Carmem Arroyo Sanchez, Expedito José Luna, Ligia Camara Pierrotti, Jan Felix Drexler, Paulo Henrique Braz-Silva, Claudio Sérgio Pannuti, Camila Malta Romano
AIDS-associated Kaposi's sarcoma (AIDS-KS) caused by human herpes virus 8 (HHV-8) is the most severe and resistant form of KS tumor. Our aim was to verify whether there is an association between HHV-8 variability and development of AIDS-KS in Brazil by comparing the HHV-8 variability between individuals without and with KS. Saliva samples and blood, when available, were analyzed by polymerase chain reaction (PCR) techniques for detection of the fragments of ORF K1 of HHV-8, which were then genotyped and analyzed regarding the genetic variability...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/26970721/effect-on-mortality-of-point-of-care-urine-based-lipoarabinomannan-testing-to-guide-tuberculosis-treatment-initiation-in-hiv-positive-hospital-inpatients-a-pragmatic-parallel-group-multicountry-open-label-randomised-controlled-trial
#5
RANDOMIZED CONTROLLED TRIAL
Jonny G Peter, Lynn S Zijenah, Duncan Chanda, Petra Clowes, Maia Lesosky, Phindile Gina, Nirja Mehta, Greg Calligaro, Carl J Lombard, Gerard Kadzirange, Tsitsi Bandason, Abidan Chansa, Namakando Liusha, Chacha Mangu, Bariki Mtafya, Henry Msila, Andrea Rachow, Michael Hoelscher, Peter Mwaba, Grant Theron, Keertan Dheda
BACKGROUND: HIV-associated tuberculosis is difficult to diagnose and results in high mortality. Frequent extra-pulmonary presentation, inability to obtain sputum, and paucibacillary samples limits the usefulness of nucleic-acid amplification tests and smear microscopy. We therefore assessed a urine-based, lateral flow, point-of-care, lipoarabinomannan assay (LAM) and the effect of a LAM-guided anti-tuberculosis treatment initiation strategy on mortality. METHODS: We did a pragmatic, randomised, parallel-group, multicentre trial in ten hospitals in Africa--four in South Africa, two in Tanzania, two in Zambia, and two in Zimbabwe...
March 19, 2016: Lancet
https://www.readbyqxmd.com/read/28301423/no-adverse-safety-or-virological-changes-two-years-following-vorinostat-in-hiv-infected-individuals-on-antiretroviral-therapy
#6
Talia M Mota, Thomas A Rasmussen, Ajantha Rhodes, Surekha Tennakoon, Ashanti Dantanarayana, Fiona Wightman, Michelle Hagenauer, Janine Roney, Tim Spelman, Damian F J Purcell, James McMahon, Jennifer F Hoy, H Miles Prince, Julian H Elliott, Sharon R Lewin
OBJECTIVE: To determine the long term effects of vorinostat on safety and virological parameters in HIV-infected individuals on suppressive antiretroviral therapy (ART). DESIGN: Prospective longitudinal observational extended follow up of 20 HIV-infected individuals on ART previously enrolled in a clinical trial of daily vorinostat 400 mg for 14 days. Extended follow up included visits at 6, 12, 18 and 24 months post enrolment in the initial clinical trial. METHODS: Cell-associated unspliced (CA-US) HIV RNA, total HIV DNA and plasma HIV RNA were quantified by PCR and, CD4+ and CD8+ T cells quantified by flow cytometry...
March 15, 2017: AIDS
https://www.readbyqxmd.com/read/28253838/predictors-and-incidence-of-sexually-transmitted-hepatitis-c-virus-infection-in-hiv-positive-men-who-have-sex-with-men
#7
Nicholas A Medland, Eric P F Chow, Catriona S Bradshaw, Timothy H R Read, Joseph J Sasadeusz, Christopher K Fairley
BACKGROUND: Sexual transmission of Hepatitis C virus (HCV) in men who have sex with men (MSM) and its interaction with HIV status, sexually transmitted infections and sexual behaviour is poorly understood. We assessed the incidence and predictors of HCV infection in HIV positive MSM. METHODS: The electronic medical record and laboratory results from HIV positive MSM in care at a large urban public specialist HIV clinic embedded in a sexual health centre in Melbourne Australia were collected...
March 2, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28301425/dolutegravir-with-tenofovir-disoproxil-fumarate-emtricitabine-as-hiv-post-exposure-prophylaxis-in-gay-and-bisexual-men
#8
John Mcallister, Janet M Towns, Anna Mcnulty, Anna B Pierce, Rosalind Foster, Robyn Richardson, Andrew Carr
OBJECTIVES: Completion rates for HIV post-exposure prophylaxis (PEP) are often low. We investigated the adherence and safety of dolutegravir (DTG 50 mg daily) with tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg (TDF-FTC) as 3-drug PEP in gay and bisexual men (GBM). DESIGN: Open-label, single-arm study at 3 sexual health clinics and 2 emergency departments in Australia. METHODS: One hundred HIV-uninfected GBM requiring PEP received DTG plus TDF-FTC for 28 days...
March 15, 2017: AIDS
https://www.readbyqxmd.com/read/27353061/virological-response-and-resistance-profile-in-hiv-1-infected-patients-starting-darunavir-containing-regimens
#9
D Armenia, D Di Carlo, G Maffongelli, V Borghi, C Alteri, F Forbici, A Bertoli, C Gori, M Giuliani, E Nicastri, M Zaccarelli, C Pinnetti, S Cicalini, G D'Offizi, F Ceccherini-Silberstein, C Mussini, A Antinori, M Andreoni, C F Perno, M M Santoro
OBJECTIVES: We evaluated the virological response in patients starting a regimen based on darunavir/ritonavir (DRV/r), which is currently the most widely used ritonavir-boosted protease inhibitor. METHODS: Data from 206 drug-naïve and 327 PI-experienced patients starting DRV/r 600/100 mg twice daily (DRV600) or 800/100 mg once daily (DRV800) were examined. The probabilities of virological success (VS) and virological rebound (VR) were evaluated in survival analyses...
January 2017: HIV Medicine
https://www.readbyqxmd.com/read/28248190/changes-in-abdominal-fat-following-antiretroviral-therapy-initiation-in-hiv-infected-individuals-correlate-with-waist-circumference-and-self-reported-changes
#10
Priya Bhagwat, Ighovwerha Ofotokun, Grace A McComsey, Todd T Brown, Carlee Moser, Catherine A Sugar, Judith S Currier
BACKGROUND: We examined whether waist circumference (WC) and self-reported abdominal size changes can estimate visceral adipose tissue (VAT) changes for those initiating antiretroviral therapy (ART). METHODS: Prospectively collected data from ACTG A5257 and its metabolic substudy, A5260s, were used for this analysis. ART-naïve HIV-infected participants were randomized to one of three contemporary ART regimens. Changes in abdominal CT-measured VAT and total adipose tissue (TAT) and DXA-measured trunk fat were tested for association with WC changes (by Pearson correlation) and categories of self-reported abdominal size changes (by ANOVA) between entry and week 96...
March 1, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28260694/a-case-study-of-chewed-truvada-%C3%A2-for-prep-maintaining-protective-drug-levels-as-measured-by-a-novel-urine-tenofovir-assay
#11
Linden Lalley-Chareczko, Devon Clark, Athena F Zuppa, Ganesh Moorthy, Caitlin Conyngham, Karam Mounzer, Helen Koenig
FTC/TDF (Truvada®) given as pre-exposure prophylaxis (PrEP) successfully blocks HIV when taken once daily prior to potential HIV exposure. A 22 year old male reported difficulty swallowing FTC/TDF for PrEP and subsequently began chewing the FTC/TDF tablets. Monthly urine samples assessed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) indicated tenofovir levels >1000 ng/mL, indicative of protection from HIV acquisition, over a 48 week period. Data from observational studies of HIV positive patients details the successful treatment of HIV using crushed FTC/TDF delivered via feeding and gastronomy tubes while small, randomized trials of healthy volunteers demonstrate bioequivalence between whole and crushed FTC/TDF...
March 6, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28233512/tuberculosis-associated-with-hiv-infection
#12
Jeffrey A Tornheim, Kelly E Dooley
Tuberculosis (TB) has recently surpassed HIV as the primary infectious disease killer worldwide, but the two diseases continue to display lethal synergy. The burden of TB is disproportionately borne by people living with HIV, particularly where HIV and poverty coexist. The impact of these diseases on one another is bidirectional, with HIV increasing risk of TB infection and disease progression and TB slowing CD4 recovery and increasing progression to AIDS and death among the HIV infected. Both antiretroviral therapy (ART) and latent TB infection (LTBI) treatment mitigate the impact of coinfection, and ART is now recommended for HIV-infected patients independent of CD4 count...
January 2017: Microbiology Spectrum
https://www.readbyqxmd.com/read/28230318/liver-related-mortality-and-hospitalizations-attributable-to-chronic-hepatitis-c-virus-coinfection-in-persons-living-with-hiv
#13
A Mena, H Meijide, I Rodríguez-Osorio, A Castro, E Poveda
OBJECTIVES: The aim of this study was to compare liver-related mortality and liver-related hospitalizations for persons living with HIV (PLWH) with and without hepatitis C virus (HCV) exposure, and to estimate the fraction of liver disease attributable to chronic HCV coinfection. METHODS: An ambispective cohort study followed PLWH between 1993 and 2014. PLWH were classified into three groups: those who were HIV-monoinfected, those who cleared HCV spontaneously and those with chronic HCV coinfection...
February 23, 2017: HIV Medicine
https://www.readbyqxmd.com/read/28170304/hiv-pre-exposure-prophylaxis-and-postexposure-prophylaxis-in-japan-context-of-use-and-directions-for-future-research-and-action
#14
Anthony S DiStefano, Makiko Takeda
Biomedical HIV prevention strategies are playing an increasingly prominent role in addressing HIV epidemics globally, but little is known about their use in Japan, where persistent HIV disparities and a recently stable, but not declining, national epidemic indicate the need for evolving approaches. We conducted an ethnographic study to determine the context of pre-exposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) use and to identify directions for future research and action in Japan. We used data from observational fieldwork in the Kansai region and Tokyo Metropolitan Area (n = 178 persons observed), qualitative interviews (n = 32), documents and web-based data sources (n = 321), and email correspondences (n = 9) in the period 2013-2016...
February 2017: AIDS Patient Care and STDs
https://www.readbyqxmd.com/read/28195560/impact-of-tenofovir-dose-adjustment-on-both-estimated-glomerular-filtration-rate-and-tenofovir-trough-concentration
#15
Sylvie Bregigeon, Caroline Solas, Olivia Faucher, Véronique Obry-Roguet, Catherine Tamalet, Isabelle Poizot-Martin
BACKGROUND: Tenofovir disoproxil fumarate (TDF)-based regimen is a treatment option for HIV-infected patients. TDF dose adjustment is recommended in patients with impaired renal function. We assessed the impact of TDF dose adjustment on renal function and tenofovir trough concentration. METHODS: Fourteen HIV patients for whom TDF dose was adjusted (1 tablet/48h) because of estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m(2), and/or due to a tenofovir trough concentration > 90 ng/mL between 2006 and 2013 were selected...
February 14, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28152024/they-might-be-giants-does-syncytium-formation-sink-or-spread-hiv-infection
#16
Alex A Compton, Olivier Schwartz
No abstract text is available yet for this article.
February 2017: PLoS Pathogens
https://www.readbyqxmd.com/read/28121714/hepatitis-delta-and-hiv-infection
#17
Vincent Soriano, Kenneth E Sherman, Pablo Barreiro
Viral liver diseases are frequent comorbidities and major contributors to death in HIV-positive individuals on antiretroviral therapy. Although cure of hepatitis C and control of hepatitis B with antivirals avert liver disease progression in most HIV-coinfected patients, the lack of satisfactory treatment for hepatitis delta virus (HDV) infection remains a major threat for developing cirrhosis and liver cancer in this population. In the European Union (EU) and North America, sexual contact has replaced injection drug use that has been the major transmission route for HDV in HIV-positive persons...
April 24, 2017: AIDS
https://www.readbyqxmd.com/read/28145050/cytochrome-2b6-polymorphism-and-efavirenz-induced-central-nervous-system-symptoms-a-substudy-of-the-anrs-alize-trial
#18
S Gallien, V Journot, M-A Loriot, H Sauvageon, P Morlat, J Reynes, V Reliquet, G Chêne, J-M Molina
OBJECTIVES: Single nucleotide polymorphisms in the cytochrome P450 (CYP) 2B6 gene have been associated with high interindividual variation in efavirenz pharmacokinetics. However, clinical data on the relationship of CYP2B6 polymorphisms with the occurrence of efavirenz-induced central nervous system (CNS) symptoms are limited. METHODS: We analysed four polymorphisms in the CYP2B6 (516 G>T), CYP3A5 (6986 A>G) and ATP-binding cassette, sub-family B, member 1 (ABCB1) (2677 G>T/A and 3435 C>T) genes in HIV-infected adults virologically suppressed on a protease inhibitor-based regimen who switched to a regimen containing emtricitabine, didanosine and efavirenz in the setting of the ANRS ALIZE trial...
February 1, 2017: HIV Medicine
https://www.readbyqxmd.com/read/28059769/cryo-em-structures-and-atomic-model-of-the-hiv-1-strand-transfer-complex-intasome
#19
Dario Oliveira Passos, Min Li, Renbin Yang, Stephanie V Rebensburg, Rodolfo Ghirlando, Youngmin Jeon, Nikoloz Shkriabai, Mamuka Kvaratskhelia, Robert Craigie, Dmitry Lyumkis
Like all retroviruses, HIV-1 irreversibly inserts a viral DNA (vDNA) copy of its RNA genome into host target DNA (tDNA). The intasome, a higher-order nucleoprotein complex composed of viral integrase (IN) and the ends of linear vDNA, mediates integration. Productive integration into host chromatin results in the formation of the strand transfer complex (STC) containing catalytically joined vDNA and tDNA. HIV-1 intasomes have been refractory to high-resolution structural studies. We used a soluble IN fusion protein to facilitate structural studies, through which we present a high-resolution cryo-electron microscopy (cryo-EM) structure of the core tetrameric HIV-1 STC and a higher-order form that adopts carboxyl-terminal domain rearrangements...
January 6, 2017: Science
https://www.readbyqxmd.com/read/28107222/romidepsin-induced-hiv-1-viremia-during-effective-art-contains-identical-viral-sequences-with-few-deleterious-mutations
#20
Anni Winckelmann, Kirston Barton, Bonnie Hiener, Timothy E Schlub, Wei Shao, Thomas A Rasmussen, Lars Østergaard, Ole S Søgaard, Martin Tolstrup, Sarah Palmer
OBJECTIVE: To investigate the origin of the HIV-1 viremia induced by the latency-reversing agent romidepsin. DESIGN: Six individuals on suppressive antiretroviral therapy received romidepsin administered intravenously once weekly for three consecutive weeks. CD4+ T-cells were obtained at baseline, following the second and third romidepsin infusion, and 10 weeks after the final romidepsin treatment. METHODS: Single-genome sequencing of the env region was used to genetically characterize the virus from proviral DNA, the transcribed cell-associated RNA and the plasma RNA pool...
January 19, 2017: AIDS
label_collection
label_collection
2825
1
2
2017-01-26 05:01:50
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"